Search research articles
Contact Us
Filters
Showing results (121-130 of 139) with videos related to
Page
of 14
Sort By:
The New England Journal of Medicine
|
June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast Cancer
François-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
Cancer Discovery
|
May 15, 2016
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Alex Pearson, Elizabeth Smyth, Irina S Babina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.
Nature Communications
|
July 17, 2021
Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA
Belinda Kingston, Rosalind J Cutts, Hannah Bye, et al.
The Lancet. Oncology
|
September 13, 2020
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C Turner, Belinda Kingston, Lucy S Kilburn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2019
Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Alex Pearson, Paula Proszek, Javier Pascual, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study
Nicholas C Turner, Judith Balmaña, Coralie Poncet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Peter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
The Lancet. Oncology
|
July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
Nicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid, Jacinta Abraham, Stephen Chan, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 139) with videos related to
Sort By:
Page
of 14
The New England Journal of Medicine
|
June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast Cancer
François-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
Cancer Discovery
|
May 15, 2016
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Alex Pearson, Elizabeth Smyth, Irina S Babina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.
Nature Communications
|
July 17, 2021
Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA
Belinda Kingston, Rosalind J Cutts, Hannah Bye, et al.
The Lancet. Oncology
|
September 13, 2020
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C Turner, Belinda Kingston, Lucy S Kilburn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2019
Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Alex Pearson, Paula Proszek, Javier Pascual, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study
Nicholas C Turner, Judith Balmaña, Coralie Poncet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Peter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
The Lancet. Oncology
|
July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
Nicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid, Jacinta Abraham, Stephen Chan, et al.
Page
of 14